European Biosimilars Group re-appoints leadership team

July 9, 2014 1:45 PM

Today the European Biosimilars Group (EBG), EGA sector group, has re-elected their leadership team.

Joerg Windisch, Chief Science Officer, Sandoz as EBG Chair; Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter, and Karl Heinz Emmert, Head Biosimilar Project Champions, Teva as Vice-Chairs; Paul Greenland, Vice-President Biologics, Hospira as Chair of the EBG-Market Access Group.

“Education and understanding are paramount to foster wider use of biosimilar medicines. While they are well understood by European Medicines Agency (EMA) regulators, there is significant work ahead of us in improving understanding amongst most other stakeholders”, commented the re-elected EBG Chair Joerg Windisch. “The EBG will reach out to stakeholders to explain how biosimilars are developed and manufactured and why they are as safe and effective as the respective originator products”, he added.

Biosimilar medicines have already improved the lives of hundreds of thousands of patients around the world. To increase access to biotherapeutic treatments in the future and to ensure the sustainability of the biosimilar medicines industry, continuous outreach and dialogue with stakeholders, including doctors, pharmacists, patients, payers and policy makers, will be essential in order to tackle the many challenges that lie ahead.

The re-elected EBG-MAG Chair Paul Greenland added: “We are on a mission to ensure the sustainability of the biosimilar medicines industry so that we can deliver on the promise of lowering the cost of health care and providing better access to biotherapeutic medicines for patients across the whole EU”.

Adrian van den Hoven, Director General of the EGA, welcomed the new leadership team which confirms the EBG as the world leading competence centre for biosimilar medicines.

Source: EGA press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!